Harrow, Inc. (NASDAQ:HROW) Shares Bought by Westside Investment Management Inc.

Westside Investment Management Inc. raised its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 6.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 173,856 shares of the company's stock after purchasing an additional 10,315 shares during the period. Harrow comprises 1.0% of Westside Investment Management Inc.'s holdings, making the stock its 22nd largest position. Westside Investment Management Inc. owned about 0.49% of Harrow worth $4,625,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of HROW. Vanguard Group Inc. raised its position in shares of Harrow by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company's stock worth $62,809,000 after purchasing an additional 5,225 shares during the last quarter. Braidwell LP raised its holdings in shares of Harrow by 106.3% during the fourth quarter. Braidwell LP now owns 907,039 shares of the company's stock valued at $30,431,000 after acquiring an additional 467,401 shares during the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Harrow by 6.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company's stock valued at $22,301,000 after acquiring an additional 41,896 shares during the last quarter. Northern Trust Corp lifted its position in shares of Harrow by 7.5% in the fourth quarter. Northern Trust Corp now owns 319,084 shares of the company's stock valued at $10,705,000 after acquiring an additional 22,266 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Harrow by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company's stock worth $8,563,000 after acquiring an additional 3,589 shares during the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on HROW. William Blair started coverage on Harrow in a report on Tuesday, June 10th. They issued an "outperform" rating on the stock. HC Wainwright increased their target price on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, May 12th. B. Riley lowered their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, BTIG Research initiated coverage on shares of Harrow in a research note on Thursday, June 12th. They issued a "buy" rating and a $62.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $61.40.

Harrow Trading Up 4.0%

Shares of NASDAQ:HROW traded up $1.21 during midday trading on Thursday, reaching $31.78. 257,698 shares of the company's stock were exchanged, compared to its average volume of 494,068. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -56.75 and a beta of 0.41. Harrow, Inc. has a fifty-two week low of $20.85 and a fifty-two week high of $59.23. The firm's 50 day simple moving average is $28.06 and its two-hundred day simple moving average is $28.95. The company has a debt-to-equity ratio of 2.01, a current ratio of 0.91 and a quick ratio of 0.85.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%. As a group, sell-side analysts forecast that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.